News
ATAI
1.790
+3.47%
0.060
ATAI Life Sciences Q4 EPS $(0.12) Beats $(0.16) Estimate, Sales $18.00K Miss $190.00K Estimate
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $0.12 per share. The company reported quarterly sales of $18.00 thousand which missed the analyst consensus estimate by 90.53 percent. ATAI Life Sciences beat the quarterly sales estimate by 25 percent.
Benzinga · 11h ago
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Atai Life Sciences announced fourth quarter and full year 2023 financial results. The company is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The company also provided corporate and clinical highlights. Atai is a subsidiary of atai Life sciences.
Barchart · 16h ago
ATAI Life Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
ATAI Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Maintains $20 Price Target
Benzinga · 1d ago
Buy Rating Affirmed for ATAI Life Sciences on Promising TRD Treatment Trial Outcomes and Strong Valuation Prospects
TipRanks · 1d ago
Atai Life: Beckley Psytech's Phase 2a Trial Of BPL-003 Positive In Treatment Resistant Depression
NASDAQ · 1d ago
Weekly Report: what happened at ATAI last week (0318-0322)?
Weekly Report · 3d ago
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Weekly Report: what happened at ATAI last week (0311-0315)?
Weekly Report · 03/18 12:09
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of March 2024. Psychedelics are associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. A new podcast by Plantscendence hosted by James Fadiman is out. A university in Israel has received clearance for its psychedelic-based clinical trial in Israel.
Benzinga · 03/16 13:58
'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Indiana lawmakers have sent a bill to the governor's desk to fund psychedelic research. The bill includes provisions to fund studies into psilocybin as a treatment for mental health conditions. The state is one of a growing number of states pursuing reform on psychedelics. Indiana lawmakers have been considering marijuana legalization.
Benzinga · 03/14 16:42
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/14 11:55
Weekly Report: what happened at ATAI last week (0304-0308)?
Weekly Report · 03/11 12:04
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation. U.S. FDA issued breakthrough therapy designation for its LSD formulation for generalized anxiety disorder. After the announcement, Mind Medicine stock surged 55% to reach a new 52-week high. Other companies focused on psychedelic drugs also traded higher on Thursday.
Seeking Alpha · 03/07 16:29
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Disorder. The medical psychedelics field is at a pivotal juncture. Clinical trial results show potential benefits for psilocybin therapy's potential for treatment of generalized anxiety disorder. Beckley Academy has published the first open-source learning framework to advance psychedelic-assisted therapy training standards. Enveric Biosciences has signed deals to license three types of drug compounds.
Benzinga · 03/04 18:48
Weekly Report: what happened at ATAI last week (0226-0301)?
Weekly Report · 03/04 12:08
Oregon House passes bill to end hard drug decriminalization
New Zealand this week reversed a ban on tobacco sales to younger generations. Thailand just announced that it would ban the use of recreational cannabis by the end of this year. Oregon is getting second thoughts on decriminalizing hard drugs. The first U.S. State to decriminalize hard drugs has declared a fentanyl state of emergency.
Seeking Alpha · 03/01 11:42
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
Management will participate in a panel discussion at the TD Cowen conference in Boston, MA, on March 4, 2024. Atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The company will be in Boston.
Barchart · 02/28 16:00
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 02/28 12:15
More
Webull provides a variety of real-time ATAI stock news. You can receive the latest news about Atai Life Sciences B.V. through multiple platforms. This information may help you make smarter investment decisions.
About ATAI
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.